Начало・Списък с акции・Bristol-Myers Squibb Co.

Bristol-Myers Squibb Co.

Отворен

СекторЗдравеопазване

66.19 1.75

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

63.88

Максимум

66.3

Ключови измерители
By Trading Economics
Приходи	1.6B 2.7B
Продажби	-1B 11B
P/E Средно за сектора	17.524 64.641
EPS	1.58
Дивидентна доходност	4.03
Марж на печалбата	23.309
Служители	32,500
EBITDA	1.5B 3.7B

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+0.57% upside

Дивиденти
By Acuity
Дивидентна доходност Средно за сектора	4.03% 2.31%
Следващи печалби	29.10.2026 г.
Следваща дата на екс-дивидент	2.10.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	9.8B 128B
Предишно отваряне	64.44
Предишно затваряне	66.19

Настроения в новините

By Acuity

48%

52%

146 / 340 Класиране в Healthcare

Bristol-Myers Squibb Co. Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

3.08.2026 г., 23:02 ч. UTC

Bristol-Myers Squibb Co shares are lower in after-market hours, with no specific news identified to explain the movement. The stock remains above its 20-day moving average.

31.07.2026 г., 19:16 ч. UTC

News

Social Media

Bristol-Myers Squibb shares rise as multiple analysts raise price targets following strong second-quarter results and an upward revision of annual guidance.

30.07.2026 г., 22:51 ч. UTC

Bristol-Myers Squibb Co. shares are lower in after-market trading, reversing earlier gains and reflecting a notable retreat from earlier highs.

29.07.2026 г., 23:36 ч. UTC

Bristol-Myers Squibb Co shares are higher in after-market trading, amid rising interest rates and inflation concerns contributing to market volatility. No specific news was identified.

28.07.2026 г., 20:06 ч. UTC

News

Bristol-Myers Squibb is rising as it enhances collaboration with Nvidia for AI in drug discovery, improving efficiency in development processes.

27.07.2026 г., 22:01 ч. UTC

Bristol-Myers Squibb Co shares are lower in after-market hours, with no specific news driving the decline amid mixed broader market performance.

24.07.2026 г., 17:56 ч. UTC

Bristol-Myers Squibb Co shares are higher, maintaining a positive trajectory since Thursday's close. No specific news was identified to explain today's price action.

23.07.2026 г., 00:01 ч. UTC

Bristol-Myers Squibb Co shares are modestly higher in after-market trading, recovering from an earlier dip and remaining above their 20-day moving average.

22.07.2026 г., 23:11 ч. UTC

Bristol-Myers Squibb Co shares are higher in after-market trading, reaching a notable rise while remaining above the 20-day moving average.

21.07.2026 г., 23:36 ч. UTC

Bristol-Myers Squibb Co. shares are near unchanged in after-market trading, remaining above their 20-day moving average amid a solid performance backdrop.

20.07.2026 г., 23:41 ч. UTC

Bristol-Myers Squibb Co. shares are trading roughly flat in after-market hours, remaining effectively unchanged since Monday's close amid no specific news.

Сравнение с други в отрасъла

Ценова промяна

Bristol-Myers Squibb Co. Прогноза

Ценова цел

By TipRanks

0.57% нагоре

12-месечна прогноза

Среден 65.84 USD 0.57%

Висок 80 USD

Нисък 40 USD

Според 20 анализатори от Wall Street, предложили 12-месечна ценова цел за Bristol-Myers Squibb Co. през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

20 ratings

Купи

Задържане

Продай

Според 20 анализатори, дали борсови рейтинги на Bristol-Myers Squibb Co. през последните 3 месеца.

Настроение

By Acuity

146 / 340 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.